Cargando…

152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures

BACKGROUND: Delayed treatment of bloodstream infections is associated with increased morbidity and mortality. Conventional methods for organism identification and susceptibility data from blood cultures can take about 2-5 days. Technological advancements in gene-based polymerase chain reaction tests...

Descripción completa

Detalles Bibliográficos
Autores principales: Nichols, Isaac, Kunapuli, Anjly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678455/
http://dx.doi.org/10.1093/ofid/ofad500.225
_version_ 1785150365615783936
author Nichols, Isaac
Kunapuli, Anjly
author_facet Nichols, Isaac
Kunapuli, Anjly
author_sort Nichols, Isaac
collection PubMed
description BACKGROUND: Delayed treatment of bloodstream infections is associated with increased morbidity and mortality. Conventional methods for organism identification and susceptibility data from blood cultures can take about 2-5 days. Technological advancements in gene-based polymerase chain reaction tests amplify DNA targets from positive blood cultures and can shorten the identification time of certain organisms and resistance genes, aiding in earlier optimization of antimicrobial therapy. METHODS: This pre/post quasi-experimental, single center study was conducted 6 months prior to and 6 months after implementation of the BCID2 panel. Patients with at least 1 positive blood culture with an organism on the BCID2 panel were included in the study. One hundred twenty-five patients were included in the pre-BCID2 arm and 114 patients in the BCID2 arm. In the BCID2 panel group, real-time alerts were received by the antimicrobial stewardship team (AST) and recommendations were made to providers. The primary outcomes were time to pathogen identification, effective therapy, and optimal therapy. RESULTS: Demographic characteristics were similar in both groups. A higher percentage of patients with multiple risk factors for bacteremia were identified in the pre-BCID2 arm (36.8% vs 20.2%). The mean time to pathogen identification (60 hrs vs 30 hrs; P < 0.0001) and time to optimal therapy (61.4 hrs vs 44.6 hrs; P=0.001) were shorter in the BCID2 arm compared to the pre-BCID2 arm. Patients in the BCID2 arm had an overall trend toward decreased mean time to effective therapy compared with the pre-BCID2 arm (17.5 hours vs. 14 hours; P=0.18). Subgroup analysis of blood cultures with vancomycin-resistant Enterococcus spp., ESBL-producing organisms, and Candida glabrata met statistical significance in all three primary outcomes. The BCID2 arm had a 21.9 hr. reduction in time to pathogen ID (49.6 v. 27.7; P=0.02), 38.9 hr. reduction in time to effective therapy (66.9 vs. 28; P=0.013), and a 54.5 hr. reduction in time to optimal therapy (89.3 vs 34.8; P=0.046). Overall, 99% of recommendations from the AST were accepted by providers. Primary Outcome Results [Figure: see text] Time to pathogen ID, Time to Effective Therapy, Time to Optimal Therapy Secondary Outcomes 1 [Figure: see text] Total length of stay, ICU length of stay, Microbiologic Cure Secondary Outcomes 2 [Figure: see text] 30 day Mortality and Recurrent bacteremia CONCLUSION: Implementation of the BCID2 panel significantly decreased time to pathogen identification and optimal therapy in patients with bacteremia. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106784552023-11-27 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures Nichols, Isaac Kunapuli, Anjly Open Forum Infect Dis Abstract BACKGROUND: Delayed treatment of bloodstream infections is associated with increased morbidity and mortality. Conventional methods for organism identification and susceptibility data from blood cultures can take about 2-5 days. Technological advancements in gene-based polymerase chain reaction tests amplify DNA targets from positive blood cultures and can shorten the identification time of certain organisms and resistance genes, aiding in earlier optimization of antimicrobial therapy. METHODS: This pre/post quasi-experimental, single center study was conducted 6 months prior to and 6 months after implementation of the BCID2 panel. Patients with at least 1 positive blood culture with an organism on the BCID2 panel were included in the study. One hundred twenty-five patients were included in the pre-BCID2 arm and 114 patients in the BCID2 arm. In the BCID2 panel group, real-time alerts were received by the antimicrobial stewardship team (AST) and recommendations were made to providers. The primary outcomes were time to pathogen identification, effective therapy, and optimal therapy. RESULTS: Demographic characteristics were similar in both groups. A higher percentage of patients with multiple risk factors for bacteremia were identified in the pre-BCID2 arm (36.8% vs 20.2%). The mean time to pathogen identification (60 hrs vs 30 hrs; P < 0.0001) and time to optimal therapy (61.4 hrs vs 44.6 hrs; P=0.001) were shorter in the BCID2 arm compared to the pre-BCID2 arm. Patients in the BCID2 arm had an overall trend toward decreased mean time to effective therapy compared with the pre-BCID2 arm (17.5 hours vs. 14 hours; P=0.18). Subgroup analysis of blood cultures with vancomycin-resistant Enterococcus spp., ESBL-producing organisms, and Candida glabrata met statistical significance in all three primary outcomes. The BCID2 arm had a 21.9 hr. reduction in time to pathogen ID (49.6 v. 27.7; P=0.02), 38.9 hr. reduction in time to effective therapy (66.9 vs. 28; P=0.013), and a 54.5 hr. reduction in time to optimal therapy (89.3 vs 34.8; P=0.046). Overall, 99% of recommendations from the AST were accepted by providers. Primary Outcome Results [Figure: see text] Time to pathogen ID, Time to Effective Therapy, Time to Optimal Therapy Secondary Outcomes 1 [Figure: see text] Total length of stay, ICU length of stay, Microbiologic Cure Secondary Outcomes 2 [Figure: see text] 30 day Mortality and Recurrent bacteremia CONCLUSION: Implementation of the BCID2 panel significantly decreased time to pathogen identification and optimal therapy in patients with bacteremia. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678455/ http://dx.doi.org/10.1093/ofid/ofad500.225 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Nichols, Isaac
Kunapuli, Anjly
152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title_full 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title_fullStr 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title_full_unstemmed 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title_short 152. Impact of BioFire FilmArray Blood Culture Identification Panel 2 (BCID2) and Antimicrobial Stewardship Interventions on Time to Optimal Antimicrobial Therapy in Patients with Positive Blood Cultures
title_sort 152. impact of biofire filmarray blood culture identification panel 2 (bcid2) and antimicrobial stewardship interventions on time to optimal antimicrobial therapy in patients with positive blood cultures
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678455/
http://dx.doi.org/10.1093/ofid/ofad500.225
work_keys_str_mv AT nicholsisaac 152impactofbiofirefilmarraybloodcultureidentificationpanel2bcid2andantimicrobialstewardshipinterventionsontimetooptimalantimicrobialtherapyinpatientswithpositivebloodcultures
AT kunapulianjly 152impactofbiofirefilmarraybloodcultureidentificationpanel2bcid2andantimicrobialstewardshipinterventionsontimetooptimalantimicrobialtherapyinpatientswithpositivebloodcultures